Philips IntelliSpace Cardiovascular software, Model 830089. Recall
Philips IntelliSpace Cardiovascular software, Model 830089.
FDA recall Class II
Ongoing
FDA lists this Class II recall for Philips IntelliSpace Cardiovascular software, Model 830089.. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-1252-2025
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Apr 4, 2024
- FDA report date
- Mar 12, 2025
- Quantity in commerce
- 139
- Distribution
- See key details
- FDA cause
- Software design
What is being recalled?
Philips IntelliSpace Cardiovascular software, Model 830089.
Affected model & UDI checker
Search the exact identifiers published for Z-1252-2025.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| 830089 | Philips IntelliSpace Cardiovascular software, Model 830089. | Check source notice | Not specified |
| Not specified | Philips IntelliSpace Cardiovascular software, Model 830089. | Check source notice | 00884838115378 |
FDA code information
Software version 7.0.0.0, UDI (01)00884838115378(11)221214(10)7.0.0.0.
Why was this product recalled?
Study data is not able to be archived, copied, or exported with the cardiovascular software version.
What actions did PHILIPS MEDICAL SYSTEMS NEDERLAND B.V. take?
The recalling firm initially issued an "Important Product Notice" dated 3/12/2024 which their consignees received on 4/4/2024 informing them that Philips had identified an issue with the IntelliSpace Cardiovascular software version 7.0 where study data is not able to be archived, copied, or exported. The notice was to explain the issue and under what circumstances it can occur, the affected products and how to identify them, the actions the customer can take to minimize the effect of the issue, and the actions planned by Philips to correct the issue. The actions were: (1) The customer may continue to use the system in accordance with its intended use; (2) If study data cannot be archived, exported, or copied from ISCV via DICOM or to a CD, update the "Reason for Study" field using less than 64 characters; (3) Circulate the notice to all users of the system so they are aware of the issue; and (4) Retain the letter with the system until Philips has implemented the software correction. Philips will contact the customer to schedule a time for a Field Service Engineer to visit their site and install a software solution to resolve the issue. No response form was enclosed. A follow-up Urgent Medical Device Correction letter dated 1/8/2025 was issued on 1/10/2025 to the U.S. consignees who have not yet received the software correction. The letter supersedes the initial 3/12/2024 letter. The 1/8/2025 letter contains updated information with respect to the potential hazard/harm associated with the issue based on the revised Health Hazard Evaluation (HHE Rev C, 02-Jan-2025). The letter also had a response form attached for completion and return no later than 30 days after receipt of the letter.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-1252-2025
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 22, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 22, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology